慢性腹膜透析患者潜在药物间相互作用的风险因素。

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-03-12 DOI:10.1159/000537968
Milorad Stojadinovic, Mirjana Lausevic, Iman Assi Milosevic, Radica Zivkovic Zaric, Tamara Kosta Jemcov, Ljiljana Komadina, Dejan Slavko Petrovic, Petar Djuric, Ana Bulatovic, Stefan Jakovljevic, Slobodan Jankovic
{"title":"慢性腹膜透析患者潜在药物间相互作用的风险因素。","authors":"Milorad Stojadinovic, Mirjana Lausevic, Iman Assi Milosevic, Radica Zivkovic Zaric, Tamara Kosta Jemcov, Ljiljana Komadina, Dejan Slavko Petrovic, Petar Djuric, Ana Bulatovic, Stefan Jakovljevic, Slobodan Jankovic","doi":"10.1159/000537968","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of potential drug-drug interactions (pDDIs) is becoming a major safety concern, as it has been previously linked to a significant number of adverse drug events and could have serious consequences for patients, including death. This is especially relevant for patients with chronic renal failure, as they are particularly vulnerable to drug-drug interactions. The aim of this study was to evaluate the prevalence and associated factors of pDDIs in patients receiving chronic peritoneal dialysis.</p><p><strong>Methods: </strong>An observational, cross-sectional study was conducted on consecutive peritoneal dialysis patients attending four tertiary care hospitals for regular monthly examination. The primary outcome was the number of pDDIs identified using Lexicomp. Potential predictors were determined using multiple linear regression.</p><p><strong>Results: </strong>Total number of patients included in the study was 140. The results showed that pDDIs were highly prevalent, especially in patients who use antiarrhythmics (p = 0.001), have diabetes mellitus (p = 0.001), recently started peritoneal dialysis (p = 0.003), or have higher number of prescribed drugs (p &lt; 0.001). Number of prescribed drugs (p &lt; 0.001) remained a significant predictor of high-risk pDDIs in addition to the female gender (p = 0.043).</p><p><strong>Conclusion: </strong>Clinicians should be particularly cautious when prescribing multiple medications to high-risk patients, such as peritoneal dialysis patients, to mitigate the risk of drug-drug interactions and associated adverse health outcomes.</p>","PeriodicalId":20209,"journal":{"name":"Pharmacology","volume":" ","pages":"147-155"},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk Factors for Potential Drug-Drug Interactions in Patients on Chronic Peritoneal Dialysis.\",\"authors\":\"Milorad Stojadinovic, Mirjana Lausevic, Iman Assi Milosevic, Radica Zivkovic Zaric, Tamara Kosta Jemcov, Ljiljana Komadina, Dejan Slavko Petrovic, Petar Djuric, Ana Bulatovic, Stefan Jakovljevic, Slobodan Jankovic\",\"doi\":\"10.1159/000537968\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The prevalence of potential drug-drug interactions (pDDIs) is becoming a major safety concern, as it has been previously linked to a significant number of adverse drug events and could have serious consequences for patients, including death. This is especially relevant for patients with chronic renal failure, as they are particularly vulnerable to drug-drug interactions. The aim of this study was to evaluate the prevalence and associated factors of pDDIs in patients receiving chronic peritoneal dialysis.</p><p><strong>Methods: </strong>An observational, cross-sectional study was conducted on consecutive peritoneal dialysis patients attending four tertiary care hospitals for regular monthly examination. The primary outcome was the number of pDDIs identified using Lexicomp. Potential predictors were determined using multiple linear regression.</p><p><strong>Results: </strong>Total number of patients included in the study was 140. The results showed that pDDIs were highly prevalent, especially in patients who use antiarrhythmics (p = 0.001), have diabetes mellitus (p = 0.001), recently started peritoneal dialysis (p = 0.003), or have higher number of prescribed drugs (p &lt; 0.001). Number of prescribed drugs (p &lt; 0.001) remained a significant predictor of high-risk pDDIs in addition to the female gender (p = 0.043).</p><p><strong>Conclusion: </strong>Clinicians should be particularly cautious when prescribing multiple medications to high-risk patients, such as peritoneal dialysis patients, to mitigate the risk of drug-drug interactions and associated adverse health outcomes.</p>\",\"PeriodicalId\":20209,\"journal\":{\"name\":\"Pharmacology\",\"volume\":\" \",\"pages\":\"147-155\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000537968\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000537968","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

导言:潜在的药物相互作用(pDDIs)正在成为一个重大的安全问题,因为它曾与大量药物不良事件有关,并可能对患者造成严重后果,包括死亡。这与慢性肾衰竭患者尤其相关,因为他们特别容易受到药物相互作用的影响。本研究旨在评估慢性腹膜透析患者中 pDDIs 的发生率和相关因素:方法:对在四家三级医院接受每月定期检查的连续腹膜透析患者进行观察性横断面研究。主要结果是使用 Lexicomp 发现的 pDDIs 数量。采用多元线性回归法确定潜在的预测因素:研究共纳入 140 名患者。结果显示,pDDIs 的发病率很高,尤其是在使用抗心律失常药物(p=0.001)、患有糖尿病(p=0.001)、最近开始腹膜透析(p=0.003)或处方药较多(pConculsion)的患者中:总之,临床医生在为腹膜透析患者等高危患者开具多种药物处方时应特别谨慎,以降低药物间相互作用和相关不良健康后果的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk Factors for Potential Drug-Drug Interactions in Patients on Chronic Peritoneal Dialysis.

Introduction: The prevalence of potential drug-drug interactions (pDDIs) is becoming a major safety concern, as it has been previously linked to a significant number of adverse drug events and could have serious consequences for patients, including death. This is especially relevant for patients with chronic renal failure, as they are particularly vulnerable to drug-drug interactions. The aim of this study was to evaluate the prevalence and associated factors of pDDIs in patients receiving chronic peritoneal dialysis.

Methods: An observational, cross-sectional study was conducted on consecutive peritoneal dialysis patients attending four tertiary care hospitals for regular monthly examination. The primary outcome was the number of pDDIs identified using Lexicomp. Potential predictors were determined using multiple linear regression.

Results: Total number of patients included in the study was 140. The results showed that pDDIs were highly prevalent, especially in patients who use antiarrhythmics (p = 0.001), have diabetes mellitus (p = 0.001), recently started peritoneal dialysis (p = 0.003), or have higher number of prescribed drugs (p < 0.001). Number of prescribed drugs (p < 0.001) remained a significant predictor of high-risk pDDIs in addition to the female gender (p = 0.043).

Conclusion: Clinicians should be particularly cautious when prescribing multiple medications to high-risk patients, such as peritoneal dialysis patients, to mitigate the risk of drug-drug interactions and associated adverse health outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmacology
Pharmacology 医学-药学
CiteScore
5.60
自引率
0.00%
发文量
52
审稿时长
6-12 weeks
期刊介绍: ''Pharmacology'' is an international forum to present and discuss current perspectives in drug research. The journal communicates research in basic and clinical pharmacology and related fields. It covers biochemical pharmacology, molecular pharmacology, immunopharmacology, drug metabolism, pharmacogenetics, analytical toxicology, neuropsychopharmacology, pharmacokinetics and clinical pharmacology. In addition to original papers and short communications of investigative findings and pharmacological profiles the journal contains reviews, comments and perspective notes; research communications of novel therapeutic agents are encouraged.
期刊最新文献
Hypoxia-treated adipose mesenchymal stem cells derived exosomes enhance the therapeutic effects on unilateral ureteral obstruction mice. Retraction Statement. Eleclazine Suppresses Ventricular Fibrillation in Failing Rabbit Hearts with Ischemia- Reperfusion Injury Undergoing Therapeutic Hypothermia. Tanshinone IIA Inhibits Hydrogen Peroxide-Induced Ferroptosis in Melanocytes through Activating Nrf2 Signaling Pathway. UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-Activated Protein Kinase-Mediated Induction of Mitophagy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1